Teon Therapeutics, Inc

Teon Therapeutics, Inc is focused on developing innovative, once-daily, oral cancer medications that enhance anti-tumor immunity and target difficult-to-treat cancers through advanced metabolic signaling pathways. Teon Therapeutics, Inc specializes in creating oral cancer therapies aimed at restoring immune function against tumors. The company was founded by Elfatih Elzein, Lina Yao, and Peter Fan, with its headquarters in Redwood City, US. Teon successfully raised USD 30 mn in Series A funding on February 22, 2021, led by Oceanpine Capital and included contributions from several investors.

The company's current valuation stands at USD 55. 64 mn. Teon Therapeutics specializes in developing innovative, once-daily, oral cancer medications aimed at restoring anti-tumor immunity. The company’s core product offerings focus on targeted therapies that exploit untapped metabolic signaling pathways, particularly emphasizing the potential benefits of G-protein coupled receptor (GPCR) signaling.

These therapies seek to address difficult-to-treat cancers by reversing immune cell suppression and halting tumor growth. Teon’s pipeline includes first- and best-in-class candidates designed to improve patient outcomes, enabling them to spend more time with loved ones rather than undergoing lengthy infusions. The company primarily targets markets with high unmet needs for effective cancer therapeutics, including the United States and Europe, focusing on oncology clinics and hospitals where patients can access these innovative treatments. Teon Therapeutics generates revenue through a model centered on the development and commercialization of its proprietary cancer therapies.

The company engages in partnerships with healthcare institutions and pharmaceutical companies to facilitate the distribution of its GPCR-directed therapies. These partnerships allow for a streamlined approach in bringing novel treatments to market while leveraging the expertise of established players in oncology. Transactions typically involve agreements for the supply of these therapies to oncology practices and hospitals, which then administer the medications to patients. Revenue is driven through direct sales in clinical settings, where healthcare providers procure the therapies to be offered as part of their treatment regimens.

Specific pricing details and structures related to these products are established during negotiations with healthcare partners and are tailored to the needs of the market. Following the Series A funding round in February 2021, Teon Therapeutics plans to invest in advancing its lead A2BR-selective antagonist, TT-702, into the clinical stage and further developing its pipeline of therapies. The company aims to expand its reach into new markets, particularly focusing on oncology practices in both the United States and Europe. The funds raised will be utilized to enhance clinical development efforts and ensure that promising candidates are brought to market efficiently.